ClinicalTrials.gg
CompletedNCT02401048Updated Jun 27, 2019Results posted

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

A Phase 1/2 interventional study of Ibrutinib and MEDI4736 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-27.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie — 2 open to participants now, 5 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · AbbVie.

Enrollment
5th of 10
61 · median 58
Started
2015
the only one that year
Phase 1/2
3 of 12
none open now
Registered
4th of 12
by date

Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 1/2, and was the 4th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

2 of the 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL)
  • sites on CT scan (>1.5 cm in longest dimension)
  • Adequate hematologic function:

    1. >1500 cells/mm3
    2. >50000 cells/mm3
    3. >8.0 g/dL
  • Adequate hepatic and renal function:

    1. or ALT ≤2.5 x
    2. ≤1.5 x ULN
    3. Estimated (Cockcroft-Gault) >40 mL/min
  • 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Received prior therapies: ibrutinib, or other BTK inhibitor and/or anti-PD1, , anti-PD-L2, anti-CD137, or CTLA-4 antibody
  • Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor
  • Primary CNS lymphoma or evidence of CNS involvement by lymphoma
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Phase 1b/ 2: Follicular lymphoma expansion cohort

    In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.

    Drug: Ibrutinib · Drug: MEDI4736

  • Experimental
    Phase 1b/ 2: Diffuse large B-cell lymphoma expansion cohort

    In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.

    Drug: Ibrutinib · Drug: MEDI4736

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1b/2 : Overall Response Rate of Number of Participants

    The response criteria is measured based on the revised criteria for malignant lymphoma described by the International Working Group for NHL (Cheson 2014).

    Time frame: From the date of first study treatment until progressive disease

Secondary outcomes

  1. Phase 1b/ 2: Duration of Response

    Time frame: Time from the date of initial response to the date of disease progression or the date of death due to any cause, whichever occurs first.

  2. Phase 1b/ 2: Progression-free Survival (PFS)

    Time frame: first dose date of study drug (ibrutinib or MEDI4736) to the first documentation of disease progression

  3. Phase 1b/2: Overall Survival

    Time frame: First dose date of study drug (ibrutinib or MEDI4736) to the date of death due to any cause

  4. Phamacokinetics: Mean Maximum Observed Plasma Concentration (Cmax) for Ibrutinib

    Maximum observed plasma concentration of ibrutinib during the dosing interval on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)

    Time frame: Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)

  5. Pharmacokinetics: Mean Time to Maximum Observed Plasma Concentration (Tmax) for Ibrutinib

    Time to corresponding maximum observed plasma concentration of ibrutinib during the dosing interval on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)

    Time frame: Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)

  6. Pharmacokinetics: Mean Area Under the Plasma Concentration-Time Curve From Time 0-24 Hours (AUC0-24h) for Ibrutinib

    Ibrutinib AUC0-24h calculated using linear trapezoidal summation after dosing from time 0 to 24 hours on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)

    Time frame: Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)

  7. Pharmacokinetics: Mean Terminal Elimination Half-Life (t1/2,Term) for Ibrutinib

    Ibrutinib terminal elimination half-life associated with the terminal slope (λz) of the semi-logarithmic plasma concentration-time curve, calculated as 0.693/λz on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)

    Time frame: Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)

  8. Pharmacokinetics: Mean Peak Plasma Concentration (Cmax) for MEDI4736

    Peak plasma concentration of MEDI4736 on Cycle 6 Day 1 (ibrutinib + MEDI)

    Time frame: Cycle 6 Day 1 (collected 10 minutes after end of infusion)

  9. Pharmacokinetics: Mean Trough Plasma Concentration (Ctrough) for MEDI4736

    Trough plasma concentration of MEDI4736 on Cycle 6 Day 1 (ibrutinib + MEDI)

    Time frame: Cycle 6 Day 1 (predose)

  10. Pharmacokinetics: MEDI4736 Accumulation Ratio for Cmax

    Accumulation ratio from Cycle 6 Day 1 to Cycle 1 Day 1 for Cmax for MEDI4736

    Time frame: Cycle 6 Day 1 (collected 10 minutes after end of infusion)

  11. Pharmacokinetics: MEDI4736 Accumulation Ratio for Ctrough

    Accumulation ratio from Cycle 6 Day 1 to Cycle 1 Day 1 for Ctrough for MEDI4736

    Time frame: Cycle 6 Day 1 (predose)

  12. Bruton Tyrosine Kinase (BTK) Occupancy

    BTK occupancy

    Time frame: ibrutinib Lead-in Day 6 or 7 pre-dose

  13. Pharmacodynamics of Ibrutinib in Subjects With Relapsed or Refractory Lymphomas

    BTK occupancy

    Time frame: Cycle 3 Day 1 Pre-dose

  14. Pharmacodynamics of MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

    Detectable Free Serum PD-L1 level

    Time frame: Cycle 3 Day1 Pre-dose

07

Results

Posted Jun 27, 2019

Participant flow

Participant flow — Overall Study
MilestonePhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Started2734
Completed54
Not completed2230

Outcome measures

PrimaryPhase 1b/2 : Overall Response Rate of Number of Participants

The response criteria is measured based on the revised criteria for malignant lymphoma described by the International Working Group for NHL (Cheson 2014).

Time frame:
From the date of first study treatment until progressive disease
Reported as:
Count of participants · Participants
Phase 1b/2 : Overall Response Rate of Number of Participants
ParticipantsPhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Phase 1b/2 : Overall Response Rate of Number of Participants78
SecondaryPhase 1b/ 2: Duration of Response
Time frame:
Time from the date of initial response to the date of disease progression or the date of death due to any cause, whichever occurs first.
Reported as:
Median · Months
Phase 1b/ 2: Duration of Response
MonthsPhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Phase 1b/ 2: Duration of Response11.3 (8.3 to NA)NA (2.5 to NA)
SecondaryPhase 1b/ 2: Progression-free Survival (PFS)
Time frame:
first dose date of study drug (ibrutinib or MEDI4736) to the first documentation of disease progression
Reported as:
Median · Months
Phase 1b/ 2: Progression-free Survival (PFS)
MonthsPhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Phase 1b/ 2: Progression-free Survival (PFS)10.2 (4.7 to 13.1)2.6 (1.5 to 4.4)
SecondaryPhase 1b/2: Overall Survival
Time frame:
First dose date of study drug (ibrutinib or MEDI4736) to the date of death due to any cause
Reported as:
Median · Months
Phase 1b/2: Overall Survival
MonthsPhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Phase 1b/2: Overall SurvivalNA (23.6 to NA)5.1 (3.7 to 10.1)
SecondaryPhamacokinetics: Mean Maximum Observed Plasma Concentration (Cmax) for Ibrutinib

Maximum observed plasma concentration of ibrutinib during the dosing interval on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)

Time frame:
Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)
Reported as:
Mean · ng/mL
Phamacokinetics: Mean Maximum Observed Plasma Concentration (Cmax) for Ibrutinib
ng/mLPhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Lead-In Day 6/7196 ± 245140 ± 117
Cycle 3 Day 1155 ± 102183 ± 101
SecondaryPharmacokinetics: Mean Time to Maximum Observed Plasma Concentration (Tmax) for Ibrutinib

Time to corresponding maximum observed plasma concentration of ibrutinib during the dosing interval on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)

Time frame:
Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)
Reported as:
Median · hour
Pharmacokinetics: Mean Time to Maximum Observed Plasma Concentration (Tmax) for Ibrutinib
hourPhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Lead-In Day 6/71.95 (0.750 to 4.00)2.01 (0.930 to 6.00)
Cycle 3 Day 12.00 (1.00 to 6.05)2.07 (1.00 to 4.97)
SecondaryPharmacokinetics: Mean Area Under the Plasma Concentration-Time Curve From Time 0-24 Hours (AUC0-24h) for Ibrutinib

Ibrutinib AUC0-24h calculated using linear trapezoidal summation after dosing from time 0 to 24 hours on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)

Time frame:
Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)
Reported as:
Mean · ng*h/mL
Pharmacokinetics: Mean Area Under the Plasma Concentration-Time Curve From Time 0-24 Hours (AUC0-24h) for Ibrutinib
ng*h/mLPhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Lead-In Day 6/71078 ± 1013936 ± 691
Cycle 3 Day 11096 ± 7481606 ± 901
SecondaryPharmacokinetics: Mean Terminal Elimination Half-Life (t1/2,Term) for Ibrutinib

Ibrutinib terminal elimination half-life associated with the terminal slope (λz) of the semi-logarithmic plasma concentration-time curve, calculated as 0.693/λz on Lead-In Day 6/7 (ibrutinib only) or Cycle 3 Day 1 (ibrutinib + MEDI)

Time frame:
Lead-In Day 6/7 or Cycle 3 Day 1 (collected at predose, 1, 2, 4, and 6 hours post-dose)
Reported as:
Mean · hour
Pharmacokinetics: Mean Terminal Elimination Half-Life (t1/2,Term) for Ibrutinib
hourPhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Lead-In Day 6/75.35 ± 2.166.43 ± 1.92
Cycle 3 Day 16.14 ± 1.965.27 ± 1.21
SecondaryPharmacokinetics: Mean Peak Plasma Concentration (Cmax) for MEDI4736

Peak plasma concentration of MEDI4736 on Cycle 6 Day 1 (ibrutinib + MEDI)

Time frame:
Cycle 6 Day 1 (collected 10 minutes after end of infusion)
Reported as:
Geometric mean · ug/mL
Pharmacokinetics: Mean Peak Plasma Concentration (Cmax) for MEDI4736
ug/mLPhase 1b/ 2: Follicular Lymphoma & DLBCL Expansion Cohort
Pharmacokinetics: Mean Peak Plasma Concentration (Cmax) for MEDI4736388 ± 14.1
SecondaryPharmacokinetics: Mean Trough Plasma Concentration (Ctrough) for MEDI4736

Trough plasma concentration of MEDI4736 on Cycle 6 Day 1 (ibrutinib + MEDI)

Time frame:
Cycle 6 Day 1 (predose)
Reported as:
Geometric mean · ug/mL
Pharmacokinetics: Mean Trough Plasma Concentration (Ctrough) for MEDI4736
ug/mLPhase 1b/ 2: Follicular Lymphoma & DLBCL Expansion Cohort
Pharmacokinetics: Mean Trough Plasma Concentration (Ctrough) for MEDI4736207 ± 12.8
SecondaryPharmacokinetics: MEDI4736 Accumulation Ratio for Cmax

Accumulation ratio from Cycle 6 Day 1 to Cycle 1 Day 1 for Cmax for MEDI4736

Time frame:
Cycle 6 Day 1 (collected 10 minutes after end of infusion)
Reported as:
Mean · ratio
Pharmacokinetics: MEDI4736 Accumulation Ratio for Cmax
ratioPhase 1b/ 2: Follicular Lymphoma & DLBCL Expansion Cohort
Pharmacokinetics: MEDI4736 Accumulation Ratio for Cmax1.90 ± 0.51
SecondaryPharmacokinetics: MEDI4736 Accumulation Ratio for Ctrough

Accumulation ratio from Cycle 6 Day 1 to Cycle 1 Day 1 for Ctrough for MEDI4736

Time frame:
Cycle 6 Day 1 (predose)
Reported as:
Mean · ratio
Pharmacokinetics: MEDI4736 Accumulation Ratio for Ctrough
ratioPhase 1b/ 2: Follicular Lymphoma & DLBCL Expansion Cohort
Pharmacokinetics: MEDI4736 Accumulation Ratio for Ctrough3.31 ± 0.8
SecondaryBruton Tyrosine Kinase (BTK) Occupancy

BTK occupancy

Time frame:
ibrutinib Lead-in Day 6 or 7 pre-dose
Reported as:
Mean · BTK % occupancy
Bruton Tyrosine Kinase (BTK) Occupancy
BTK % occupancyPhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Bruton Tyrosine Kinase (BTK) Occupancy77.6 ± 8.491.2 ± 3.4
SecondaryPharmacodynamics of Ibrutinib in Subjects With Relapsed or Refractory Lymphomas

BTK occupancy

Time frame:
Cycle 3 Day 1 Pre-dose
Reported as:
Mean · BTK % occupancy
Pharmacodynamics of Ibrutinib in Subjects With Relapsed or Refractory Lymphomas
BTK % occupancyPhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Pharmacodynamics of Ibrutinib in Subjects With Relapsed or Refractory Lymphomas83.1 ± 9.494.4 ± 3.1
SecondaryPharmacodynamics of MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Detectable Free Serum PD-L1 level

Time frame:
Cycle 3 Day1 Pre-dose
Reported as:
Number · pg/mL
Pharmacodynamics of MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
pg/mLPhase 1b/ 2: Follicular Lymphoma Expansion CohortPhase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort
Pharmacodynamics of MEDI4736 in Subjects With Relapsed or Refractory Lymphomas18.4NA

Adverse events

Collected over All AEs, whether serious or non-serious, are documented in the source documents from the time the signed and dated ICF is obtained until 30 days following the last dose of ibrutinib and 90 days following the last dose of MEDI4736.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b/2: Follicular Lymphoma Expansion Cohort:6/27 (22.2%)10/27 (37%)27/27 (100%)
Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort:24/34 (70.6%)23/34 (67.6%)33/34 (97.1%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventPhase 1b/2: Follicular Lymphoma Expansion Cohort:Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort:
Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/276/34
Atrial FibrillationCardiac disorders1/273/34
LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/273/34
Muscular weaknessMusculoskeletal and connective tissue disorders2/270/34
PyrexiaGeneral disorders0/272/34
PneumoniaInfections and infestations0/272/34
Urinary tract infectionInfections and infestations0/272/34
HypercalcaemiaMetabolism and nutrition disorders0/272/34
NeutropeniaBlood and lymphatic system disorders1/271/34
Febrile NeutropeniaBlood and lymphatic system disorders1/270/34
Most frequent other events
Showing 10 of 70
Most frequent other events
EventPhase 1b/2: Follicular Lymphoma Expansion Cohort:Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort:
DiarrhoeaGastrointestinal disorders16/2716/34
FatigueGeneral disorders12/2716/34
Upper respiratory tract infectionInfections and infestations12/273/34
Oedema peripheralGeneral disorders7/2713/34
NauseaGastrointestinal disorders9/2712/34
NeutropeniaBlood and lymphatic system disorders6/2711/34
Decreased appetiteMetabolism and nutrition disorders8/2711/34
CoughRespiratory, thoracic and mediastinal disorders8/276/34
Muscle spasmsMusculoskeletal and connective tissue disorders6/273/34
HeadacheNervous system disorders6/271/34

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase 1b/2: Follicular Lymphoma Expansion Cohort:Phase 1b/2: Diffuse Large B-cell Lymphoma Expansion Cohort:Total
<=18 years000
Between 18 and 65 years191534
>=65 years81927
Age, Continuous
Age, Continuous(years)Phase 1b/2: Follicular Lymphoma Expansion Cohort:Phase 1b/2: Diffuse Large B-cell Lymphoma Expansion Cohort:Total
Mean57 ± 11.8861.2 ± 15.1559.3 ± 13.85
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b/2: Follicular Lymphoma Expansion Cohort:Phase 1b/2: Diffuse Large B-cell Lymphoma Expansion Cohort:Total
Female101323
Male172138
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b/2: Follicular Lymphoma Expansion Cohort:Phase 1b/2: Diffuse Large B-cell Lymphoma Expansion Cohort:Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American112
White233255
More than one race000
Unknown or Not Reported314
Region of Enrollment
Region of Enrollment(participants)Phase 1b/2: Follicular Lymphoma Expansion Cohort:Phase 1b/2: Diffuse Large B-cell Lymphoma Expansion Cohort:Total
United States273461
08

Study locations

11 sites
  • Site-0397
    Birmingham, Alabama 35294, United States
  • Site-0047
    Duarte, California 91010, United States
  • Site-0038
    Stanford, California 94305, United States
  • Site-0388
    Miami, Florida 33136, United States
  • Site-0126
    Chicago, Illinois 60637, United States
  • Site-0020/0173
    Boston, Massachusetts 02114, United States
  • Site-0729
    Ann Arbor, Michigan 48109, United States
  • Site-0130
    Detroit, Michigan 48201, United States
  • Site-0343
    Hackensack, New Jersey 07601, United States
  • Site-0402
    Philadelphia, Pennsylvania 19104, United States
  • Site-0114
    Seattle, Washington 98104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Nov 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2019, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2015
First posted
Mar 27, 2015
Start
May 2015
Primary completionActual
Nov 2017
CompletionActual
Nov 2017
Results first posted
Jun 27, 2019
Last update
Jun 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02401048
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Mar 27, 2015
Start date
May 2015
Primary completion
Nov 2017
Completion
Nov 2017
Results posted
Jun 27, 2019
Last update
Jun 27, 2019

Study contacts

Emily Liu
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion